Home > Search Clinical Trials > All > Trial Details

Clinical Trial Details
Generation of Customized Anti-Tumor T Cells From Human Pluripotent Stem Cells (hPS) Derived Embryoid Bodies (EB) For Immunotherapy of Human Melanoma.
Clinical Trial ( IRB ) #: 14-017-2
Title: Generation of Customized Anti-Tumor T Cells From Human Pluripotent Stem Cells (hPS) Derived Embryoid Bodies (EB) For Immunotherapy of Human Melanoma.
Principal Investigator: Dr. Arvind Chhabra
Description: Our study aims to combine the self-renewable potential of human pluripotent stem cells (hPS) with the TCR engineering technology to create a large reservoir of patient specific, immunologically matched, customized anti-tumor T cells with defined functional characteristics. The central hypothesis driving our study is that “the hPS derived EB can be utilized as an efficient model to study the differentiation of HSC precursors into T cells, in situ. Understanding the molecular mechanism of in-situ T cell generation in EB, in combination with the TCR engineering approach, could be utilized to generate naive, patient specific, customized anti-tumor T cells, for an effective cancer immunotherapy”.
Classification:
  Cancer - General
  Infectious Disease/Immune System (HIV/AIDS, Hepatitis)
Eligibility Criteria: Check with study contact
How to Contact: Harriet Zawistowski. Telephone: (860) 679-1658. Email: zawistowski@uchc.edu
Enrollment Status/Comments: Enrolling/recruiting. For current recruitment status, please check with study contact.